Pharma Mar, S.A. (BME:PHM)
Spain · Delayed Price · Currency is EUR 83.60
0.00 (0.00%)
Aug 27, 2026, 5:35 PM CET
Pharma Mar Stock Forecast
Stock Price Forecast
According to 9 analysts polled by S&P Global, Pharma Mar stock has a consensus rating of "Buy" and an average price target of €104.39. The average 1-year stock price forecast is 24.87% higher than the current stock price, while the lowest is €85.50 (+2.27%) and the highest is €125.00 (+49.52%).
Price Target: €104.39 (+24.87%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Pharma Mar stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 9 | 9 | 9 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Buy Maintains €100.00 | Buy | Maintains | €100.00 | +19.62% | Aug 10, 2026 |
| BTIG | BTIG | Buy Initiates €121.00 | Buy | Initiates | €121.00 | +44.74% | Apr 23, 2026 |
Financial Forecast
Revenue This Year
210.96M
from 221.39M
Decreased by -4.71%
Revenue Next Year
305.46M
from 210.96M
Increased by 44.80%
EPS This Year
2.37
from 4.30
Decreased by -45.00%
EPS Next Year
6.81
from 2.37
Increased by 187.84%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.